. (2024). Eligibility of patients with chronic obstructive pulmonary disease for inclusion in randomised control trials investigating triple therapy: a study using routinely collected data. Respir Res, 25, 43. http://doi.org/10.1186/s12931-024-02672-x
Disease Progression
. (2023). Exploring the impact of varying definitions of exacerbations of chronic obstructive pulmonary disease in routinely collected electronic medical records. Plos One, 18, e0292876. http://doi.org/10.1371/journal.pone.0292876
. (2023). Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK. Int J Chron Obstruct Pulmon Dis, 18, 2673-2685. http://doi.org/10.2147/copd.s413947
. (2022). Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy. Int J Chron Obstruct Pulmon Dis, 17, 2187-2200. http://doi.org/10.2147/copd.s378649
. (2022). Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France. Bmj Open Respir Res, 9. http://doi.org/10.1136/bmjresp-2021-001150
. (2022). Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data. Plos One, 17, e0269970. http://doi.org/10.1371/journal.pone.0269970
. (2021). Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. Int J Chron Obstruct Pulmon Dis, 16, 2591-2604. http://doi.org/10.2147/copd.s318969
. (2022). Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. Int J Chron Obstruct Pulmon Dis, 17, 427-437. http://doi.org/10.2147/copd.s346591